Compositions and methods for treating retinal degradation

Patent metadata

Field	Value
Publication number	US-11717520-B2
Application number	US-202117189803-A
Country	US
Kind code	B2
Filing date	Mar 2, 2021
Priority date	Feb 26, 2015
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

The present disclosure relates to compounds and compositions that inhibit the NLRP3 inflammasome, for example,or a pharmaceutically acceptable salt thereof. Also disclosed are methods for treating, and in particular methods for treating macular degeneration, e.g., dry age-related macular degeneration (AMD) and wet AMD, Alzheimer's disease, multiple sclerosis, and Parkinson's disease, using compounds and compositions that inhibit the NLRP3 inflammasome.

First claim

What is claimed is:

1. A compound having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having a structure selected from the group consisting of:

and

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

7. A method for treating a condition selected from dry age related macular degeneration (AMD) and wet AMD, comprising:
administering an effective amount of a compound of claim 1 to a subject having macular degeneration.

8. A method of treating a condition associated with inflammasome activation, wherein the condition is selected from dry AMD, wet AMD, Parkinson's disease, Alzheimer's disease, and multiple sclerosis, comprising administering to a subject having said condition an effective amount of a compound having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 7 , wherein the condition is wet AMD.

11. The method of claim 10 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 7 , wherein the condition is dry AMD.

13. The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 8 , wherein the condition is Alzheimer's disease.

15. The method of claim 14 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The method of claim 8 , wherein the condition is multiple sclerosis.

17. The method of claim 16 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The method of claim 8 , wherein the condition is Parkinson's disease.

19. The method of claim 18 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Univ Kentucky Res Found

Inventors

• Ambati Jayakrishna
• Fowler Benjamin
• Ambati Kameshwari

Classifications

• C07D411/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title